Radiotherapy & Oncology
Volume 96, Issue 3 , Pages 325-327 , September 2010

PET for radiation treatment planning of brain tumours

  • Anca-L. Grosu

      Affiliations

    • Department of Radiation Oncology, University of Freiburg, Germany
    • Corresponding Author InformationCorresponding author. Address: Department of Radiation Oncology, Albert Ludwigs University Freiburg, Robert Koch Str. 3, Freiburg 79106, Germany.
    • ,
  • Wolfgang A. Weber

      Affiliations

    • Department of Nuclear Medicine, University of Freiburg, Germany

Received 28 June 2010 ,Revised 1 August 2010 ,Accepted 10 August 2010.

References 

  1. Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9:453–461
  2. Langen KJ, Jarosch M, Muhlensiepen H, et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol. 2003;30:501–508
  3. Weber WA, Wester HJ, Grosu AL, et al. O-2(18F)Fluorethyl-l-tyrosine and l-(methyl-11C)-methionine uptake in brain tumors: initial results of a comparative study. Eur J Nucl Med. 2000;27:542–549
  4. Grosu AL, Weber WA, Riedl E et al. An interindividual comparison of O-(2-[18F]Fluoroethyl)-l-tyrosine (FET) and l-[methyl-11C]methionine (MET) PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys 2010;doi:10.1016/j.ijrobp.2010.07.022.
  5. Grosu AL, Weber WA, Feldmann HJ, et al. First experience with I-123-alpha-methyl-tyrosine SPECT in the 3-D radiation treatment planning of brain gliomas. Int J Rad Oncol Biol Phys. 2000;47:517–527
  6. Weber WA, Dick S, Reidl G, et al. Correlation between postoperative 3-(123I)-Iodo-l-alpha-methyltyrosine uptake and survival in patients with gliomas. J Nucl Med. 2001;42:1144–1150
  7. Grosu AL, Feldmann HJ, Dick S, et al. Implications of IMT-SPECT for postoperative radiation treatment planning in patients with gliomas. Int J Rad Oncol Biol Phys. 2002;54:842–854
  8. Grosu AL, Lachner R, Wiedenmann N, et al. Validation of a method for automatic fusion of CT- and C11-methionine-PET datasets of the brain for stereotactic radiotherapy using a LINAC. First clinical experience. Int J Rad Oncol Biol Phys. 2003;56:1450–1463
  9. Grosu AL, Weber AW, Riedel E, et al. l-(Methyl-11C) methionine positron emissions tomography for target delineation in resected high grade gliomas before radiation therapy. Int J Rad Oncol Biol Phys. 2005;63:64–74
  10. Lee IH, Piert M, Gomez-Hassan D, et al. Association of 11C-methionine PET uptake with the site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Rad Oncol Biol Phys. 2009;73:479–485
  11. Weber DC, Casanova N, Zilli T, et al. Recurrence pattern after [(18)F]fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma: a prospective study. Radiother Oncol. 2009;93:586–592
  12. Grosu AL, Weber WA, Franz M, et al. Re-Irradiation of recurrent high grade gliomas using amino-acids-PET(SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Rad Oncol Biol Phys. 2005;63:511–519
  13. Weber WA, Grosu AL, Czernin J. Technology insight: advances in molecular imaging and an appraisal of PET/CT scanning. Nat Clin Pract Oncol. 2008;5:160–170
  14. Gross MW, Weber WA, Feldmann HJ, et al. The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys. 1998;41:989–995
  15. Grosu AL, Weber WA, Astner S, et al. 11C-Methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int J Rad Oncol Biol Phys. 2006;66:339–344
  16. Astner ST, Dobrei-Ciuchendea M, Essler M, et al. Effect of 11C-methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas. Int J Radiat Oncol Biol Phys. 2008;72:1161–1167
  17. Milker-Zabel S, Zabel-du Bois A, Henze M, et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006;65:222–227
  18. Gehler B, Paulsen F, Öksüz MÖ, et al. [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol. 2009;4:56
  19. Astner ST, Bundschuh RA, Beer AJ, et al. Assessment of tumor volumes in skull base glomus tumors using Gluc-Lys[(18)F]-TOCA positron emission tomography. Int J Radiat Oncol Biol Phys. 2009;73:1135–1140
  20. Ullrich R, Backes H, Li H, et al. Glioma proliferation as assessed by 3’-fluoro-3’-deoxy-l-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res. 2008;14:2049–2055
  21. Valk PE, Mathis CA, Prados MD, et al. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med. 1992;33:2133–2137
  22. Beer AJ, Grosu AL, Carlsen J, et al. Feasibility of (18F)Galacto-RGD PET for imaging of αvβ3 expression on noevasculature in patients with squamous cell carcinoma of head and neck. Clin Cancer Res. 2007;13:6610–6616

PII: S0167-8140(10)00461-5

doi: 10.1016/j.radonc.2010.08.001

Radiotherapy & Oncology
Volume 96, Issue 3 , Pages 325-327 , September 2010

Article Tools

* Image Usage & Resolution